FDA panel to review NSAIDs this month

Share this article:

An FDA advisory panel convenes in six days to consider revoking the over-the-counter status of some NSAIDs. Drugstore News reports that the group will meet February 10 to discuss the risks these drugs may pose to heart health. DSN says the group will also discuss whether Pfizer should continue its Celebrex safety study which compares the arthritis pain reliever to ibuprofen and naproxen, since naproxen is considered safer.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.